Study on hemorrhage complications of Coadministration of Dronedarone and Rivaroxaban after Catheter Ablation for Atrial Fibrillation

Objectives To compare the hemorrhage complications between the coadministration of dronedarone and rivaroxaban and that of amiodarone and rivaroxaban after radiofrequency ablation in patients with atrial fibrillation (AF). Methods Fifty patients with AF and abnormal thyroid function were administered dronedarone and rivaroxaban (Group D-R) after catheter ablation, and fifty patients with AF and normal thyroid function received dronedarone and rivaroxaban (Group A-R) after the operation were matched using propensity score matching. All patients returned for follow-up once a month for 3 months. The incidence of minor hemorrhage, massive hemorrhage, thromboembolism, and the recurrence rate of atrial fibrillation were observed. Results No significant difference was noted in the incidence of postoperative minor bleeding between the Group D-R and the Group A-R（2% versus 4%, P=0.558）, and no massive hemorrhage and ischemic events were detected in both groups. Also, no significant difference was observed in recurrence rate of AF between two groups(18% versus 16%, P=0.790). Conclusions Compared to the coadministration of amiodarone and rivaroxaban, that of dronedarone and rivaroxaban does not increase the risk of hemorrhage, thromboembolism and AF recurrence after radiofrequency ablation.